AZLI + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis

Trial Timeline

Apr 1, 2011 → Jul 1, 2013

NCT ID

NCT01314716

About AZLI + Placebo

AZLI + Placebo is a phase 3 stage product being developed by Gilead Sciences for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01314716. Target conditions include Bronchiectasis.

What happened to similar drugs?

1 of 9 similar drugs in Bronchiectasis were approved

Approved (1) Terminated (2) Active (7)

✅Aztreonam lysineGilead SciencesApproved

❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3

🔄Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3

🔄Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3

🔄AZLI + PlaceboGilead SciencesPhase 3

🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3

🔄Brensocatib 10 mg + Brensocatib 25 mg + PlaceboInsmedPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03219164	Phase 3	Terminated	Nov 28, 2017	Sep 23, 2021	Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization
NCT01313624	Phase 3	Completed	Apr 1, 2011	Jun 1, 2013	Bronchiectasis
NCT01314716	Phase 3	Completed	Apr 1, 2011	Jul 1, 2013	Bronchiectasis
NCT01059565	Phase 3	Completed	Feb 1, 2010	Jan 1, 2012	Cystic Fibrosis

Competing Products

20 competing products in Bronchiectasis

See all competitors

Product	Company	Stage	Hype Score
Benralizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	32
AZD9668 + Placebo	AstraZeneca	Phase 2	35
AZD5069 + Placebo	AstraZeneca	Phase 2	35
AZD0292	AstraZeneca	Phase 2	42
TIP + TIP and placebo + Placebo	Novartis	Phase 2	35
Ciprofloxacin DPI (BAYQ3939) + Placebo	Novartis	Phase 3	40
Placebo to Ciprofloxacin DPI (BAYQ3939)	Novartis	Pre-clinical	26
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo	Novartis	Phase 3	40
QBW251 + Placebo	Novartis	Phase 2	27
Ciprofloxacin (Cipro, BAYQ3939) + Placebo	Novartis	Phase 2	35
AZLI + Placebo	Gilead Sciences	Phase 3	40
Aztreonam lysine	Gilead Sciences	Approved	35
AZLI	Gilead Sciences	Phase 2	35
Itepekimab (SAR440340) + Placebo	Sanofi	Phase 2	35
CSL787 + Placebo	CSL	Phase 1	29
CSL787 + Placebo	CSL	Phase 2	42
HSK31858, tablet + Placebo	Haisco Pharmaceutical Group	Phase 3	47
HSK31858 + placebo	Haisco Pharmaceutical Group	Phase 2	35
Group A + Group B	Bayer	Pre-clinical	23
BAY85-8501 + Placebo	Bayer	Phase 2	32